
BioMarin Pharma gains with analyst upgrade, patent deal, and $275M acquisition boosting growth.
BioMarin Pharmaceutical Inc. saw its stock gain momentum after Jefferies raised its price target to $105, signaling strong confidence in the biotech firm. The company secured new revenue streams through a patent settlement with Ascendis Pharma, earni...


